

ABIOMED INC  
Form SD  
May 24, 2018

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM SD**

**Specialized Disclosure Report**

**ABIOMED, Inc.**

**(Exact Name of Registrant as Specified in its Charter)**

**Delaware**  
**(State or other jurisdiction**  
  
**of incorporation)**

**001-09585**  
**(Commission**  
  
**File Number)**

**04-2743260**  
**(IRS Employer**  
  
**Identification No.)**

**22 Cherry Hill Drive, Danvers, Massachusetts**  
**(Address of principal executive offices)**

**01923**  
**(Zip Code)**

**Registrant's telephone number, including area code (978) 646-1400**

**Todd A. Trapp**

**978-646-1400**

**(Name and telephone number, including area code, of the person to contact in connection with this report)**

Check the appropriate box to indicate the rule pursuant to which this form is being filed, and provide the period to which the information in this form applies:

Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1 to December 31, 2017.

## **Section 1 Conflict Minerals Disclosure**

### **Item 1.01 Conflict Minerals Disclosure and Report Conflict Minerals Disclosure**

This Form SD of ABIOMED, Inc. (the Company ) is filed pursuant to Rule 13p-1 promulgated under the Securities Exchange Act of 1934, as amended, for the reporting period from January 1, 2017 to December 31, 2017.

A copy of our Conflict Minerals Report is filed herewith as Exhibit 1.01 hereto and is publicly available at: [www.abiomed.com](http://www.abiomed.com).

Information appearing on [www.abiomed.com](http://www.abiomed.com) is not a part of, and is not incorporated by reference into, this Form SD.

### **Item 1.02 Exhibit**

The Company is hereby filing its Conflict Minerals Report described in Item 1.01 as Exhibit 1.01 to this Report.

## **Section 2 Exhibits**

### **Item 2.01 Exhibits**

The following exhibit is filed as part of this report:

Exhibit 1.01 Conflict Minerals Report for the calendar year ended December 31, 2017.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 24, 2018

ABIOMED, INC.

(Registrant)

By: /s/ Todd A. Trapp  
Todd A. Trapp  
Vice President, Chief Financial Officer